Is AstraZeneca plc Selling Off The Family Silver To Support Short-Term Growth?

AstraZeneca plc (LON: AZN) is using one-off sales to boost revenue but will this hurt long-term performance?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca’s (LSE: AZN) first-half results beat expectations but once the dust surrounding the release died down, analysts started to pick holes in the company’s numbers. 

A key figure that attracted analysts’ attention was the level of revenue stemming from Astra’s “externalisation deals”. These deals are part of management’s plan to boost short-term revenue while outsourcing drug development costs to other parties. 

However, while Astra’s externalisation deals are boosting figures now, there’s concern that the company is selling off some potentially lucrative treatments at knock-down prices.

Growing sales

Astra reported organic sales of $11.6bn for the first-half of 2015, down 10% year-on-year. Including an additional $800m from externalisation deals, sales only declined 6% year-on-year, which is a significant improvement. 

Astra has been busy offloading non-core drugs this year. Some of the assets divested include an experimental dementia drug, which was placed into a partnership with Eli Lilly of the US, co-marketing rights for a new constipation pill sold to Daiichi Sankyo of Japan for $200m, and all non-US rights for Entocort, a treatment for Crohn’s disease. 

Other larger externalisation deals include a $450m collaboration on immunotherapies with Celgene, one of the biggest names in the US biotech industry. 

City analysts believe that these deals are misleading shareholders. They have been called fill-the-gap revenue deals of “questionable sustainability.” Moreover, Astra’s management has been accused of engineering earnings by using these deals to help the group meet lofty growth targets. 

Still, there’s no denying that Astra’s turnaround is taking shape. Indeed, while some analysts may be sceptical about the sustainability of the company’s revenue growth, group costs are falling, and Astra has an exciting pipeline of new treatments under development. 

The group is expecting to receive the approval for two new drugs — Iressa (lung cancer) and Faslodex (breast cancer) — during the second half of 2015. Regulatory submissions for new lung cancer and ovarian tumours medication is also expected. 

But the most exciting drug Astra has under development at present is AZD9291. 

Exciting prospects

AZD9291, which is yet to receive a proper name, is being pushed through the development pipeline at breakneck speed. The drug is designed for the treatment for lung cancer and has been undergoing clinical tests for two years. Astra has already submitted AZD9291 for regulatory approval, and if approved, the treatment could catapult Astra’s sales higher.

All in all, Astra has more than 50 treatment trials planned for this year, with several launches planned between now and 2017. According to City analysts, three of these treatments have the potential to be blockbusters, which can return the company to growth by 2017; as targeted by management. 

Astra is expected to generate $6.9bn of oncology franchise sales by 2023, up from a low of $2.8bn reported this year. Profit margins are expected to expand significantly over this period. In total, Astra has 222 new products under development. 

Paid to wait

It will take time for Astra to return to growth, but the company is one of the FTSE 100’s dividend champions, and investors will be paid to wait. 

At present, Astra supports an attractive dividend yield of 4.2%, and this payout should be here to stay, as it is linked to management compensation.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »